Paper Details

  1. Home
  2. Paper Details

Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects.

Author: Abou-SettaAhmed M, ClericiGraziano, Di RenzoGian Carlo, WexJaro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Atosiban is cost-saving compared to betamimetics in the treatment of preterm labour in Italy. Atosiban is as effective as betamimetics in delaying preterm birth, but it has fewer side effects.
Paper Details　
Original Abstract of the Article :
The aim of this study was to determine the cost effectiveness of atosiban compared to betamimetics in the treatment of preterm labour within the Italian setting. A systematic literature review identified randomised controlled trials (RCTs) comparing atosiban with betamimetics. Meta-analysis of nine ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejogrb.2011.04.009

データ提供：米国国立医学図書館（NLM）

Cost-Effective Treatment for Preterm Labor in Italy

The field of obstetrics is constantly seeking ways to improve the health outcomes of mothers and their babies. This research delves into the cost-effectiveness of atosiban compared to betamimetics in the treatment of preterm labor in Italy. They used a systematic literature review to identify randomized controlled trials (RCTs) that compared these two medications. Their meta-analysis of nine RCTs found that atosiban and betamimetics had similar efficacy in delaying preterm birth by at least 48 hours. However, atosiban was associated with significantly fewer adverse events. The researchers found that atosiban is cost-saving versus ritodrine or isoxuprine, with savings of €657 per patient from the National Health Service payer's perspective and €299 to €189 from the hospital's perspective. This research underscores the importance of considering the cost-effectiveness of treatments in clinical decision-making.

Atosiban: A Safer and More Economical Option

This study's results show that atosiban is a safer and more economical option for treating preterm labor in Italy. The researchers estimate that using atosiban instead of betamimetics could save the Italian National Health Service over €13 million annually. The study's findings demonstrate the importance of considering the cost-effectiveness of treatment options, especially in the context of healthcare resource constraints.

Safeguarding Mothers and Babies

Preterm labor is a significant concern for mothers and their babies, leading to potential health complications. This study highlights the importance of using safe and effective treatment options for preterm labor. Atosiban's superior safety profile and cost-effectiveness make it a valuable tool in the fight against preterm birth.

Dr.Camel's Conclusion

As a fellow researcher, I was impressed by the thoroughness of this study and the impact it could have on the lives of pregnant women in Italy. The study's findings provide valuable insights into the cost-effectiveness and safety of treatment options for preterm labor. This research serves as a guiding light, illuminating the path towards a future where mothers and their babies can thrive.

Date :
  1. Date Completed 2012-01-25
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21620558

DOI: Digital Object Identifier

10.1016/j.ejogrb.2011.04.009

Related Literature

Article Analysis
・Side Effects of isoxsuprine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.